Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Debamestrocel - BrainStorm Cell Therapeutics

Next Previous
Drug Profile

Debamestrocel - BrainStorm Cell Therapeutics

Alternative Names: Autologous bone marrow derived mesenchymal stem cell therapy - BrainStorm Cell therapeutics; Autologous MSC-NTF; Bone-marrow-derived-mesenchymal-stem-cells-BrainStorm; GDNF therapy; GDNf-stem-cell-therapy-BrainStorm-Cell-Therapeutics; Glial-cell-line-derived-neurotrophic-factor-producing-adult-bone-marrow-derived-stem-cell-therapy-BrainStorm Cell Therapeutics; Glial-cell-line-derived-neurotrophic-factor-stem-cell-therapy-BrainStorm; MSC-NTF; MSC-NTF cell; MSC-NTF-BrainStorm-Cell-Therapeutics; Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics; Neurotrophic factor-secreting stem cell therapy; Neurotrophic-factor-producing-adult-stem-cell-therapy-BrainStorm; NurOwn; NurOwn-GDNF-therapy; NurOwn™ program one

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tel Aviv University
  • Developer Brainstorm Cell Therapeutics; Hadassah Medical Organization; Tel Aviv University
  • Class Exosome therapies; Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Dopaminergic cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis
  • Preclinical Acute lung injury; Peripheral nerve injuries
  • No development reported Autism spectrum disorder; Huntington's disease; Parkinson's disease; Sciatica; Spinal cord injuries

Most Recent Events

  • 28 Aug 2025 No recent reports of development identified for preclinical development in Autism-spectrum-disorder in Israel (Intrathecal, Injection)
  • 28 Aug 2025 No recent reports of development identified for preclinical development in Huntington's-disease in Israel (Intrathecal, Injection)
  • 28 Aug 2025 No recent reports of development identified for preclinical development in Parkinson's-disease in Israel (Intrathecal, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top